9 March 2026

BioCaptiva secures £1.6m to accelerate blood sample technology and expand product offering.

The funding round was led by Archangels to support product development and market entry.

£1.6M

BioCaptiva is a medical technology company that develops blood sample preparation technology for cancer research and diagnostics.

BioCaptiva has secured £1.6m in a new funding round led by Archangels. The capital will be used to accelerate the development of the company blood sample preparation technology and expand its product offering.

Additional backing for the round came from Old College Capital, BBI, Scottish Enterprise, and EverQuest Capital Partners. The investment coincides with the launch of the company first research kits in Boston as it enters the US market.

The firm has also strengthened its leadership team with the appointment of Alan Schafer as chief technology officer. Schafer brings extensive industry experience from previous senior roles across the biotechnology sector.

From the founder

"Oncology is an exciting and vibrant sector. The scientists and technologists have been doing incredible things based upon the samples that they’re given, but there hasn’t been any particular movement in how the samples are prepared for years. Our msX platform has the potential to revolutionise how samples are collected, allowing for larger samples, faster extraction, simpler processing, and fully automatable capabilities."

Jeremy Wheeler

CEO at BioCaptiva

Investor perspective

"BIOCAPTIVA is at an inflexion point in its growth trajectory with the launch of its newmsX beads. The market potential for the technology is remarkable, and with the products, the senior leadership and the research and development capability within the business, we’re confident about the future success of the BIOCAPTIVA."